Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head Injuries, Penetrating | 7 | 2023 | 55 | 1.800 |
Why?
|
| Wounds, Gunshot | 3 | 2020 | 81 | 0.980 |
Why?
|
| Craniotomy | 2 | 2020 | 88 | 0.840 |
Why?
|
| tau Proteins | 6 | 2009 | 67 | 0.810 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 6 | 0.730 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2020 | 25 | 0.720 |
Why?
|
| Brain Neoplasms | 6 | 2016 | 774 | 0.700 |
Why?
|
| Fasciitis | 1 | 2019 | 10 | 0.700 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 102 | 0.690 |
Why?
|
| Orbital Diseases | 1 | 2019 | 21 | 0.680 |
Why?
|
| Neurosurgical Procedures | 5 | 2023 | 221 | 0.630 |
Why?
|
| Brain Diseases | 1 | 2019 | 184 | 0.630 |
Why?
|
| Glioma | 3 | 2016 | 290 | 0.570 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2018 | 85 | 0.550 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2016 | 10 | 0.540 |
Why?
|
| Meningitis | 1 | 2016 | 20 | 0.540 |
Why?
|
| Pituitary Neoplasms | 3 | 2024 | 67 | 0.490 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 188 | 0.480 |
Why?
|
| Streptavidin | 1 | 2013 | 14 | 0.440 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 35 | 0.440 |
Why?
|
| Ferric Compounds | 1 | 2013 | 38 | 0.430 |
Why?
|
| Endoscopy | 1 | 2016 | 339 | 0.420 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 105 | 0.410 |
Why?
|
| Brain | 4 | 2020 | 2257 | 0.400 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 565 | 0.380 |
Why?
|
| Antibodies | 1 | 2013 | 354 | 0.380 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2022 | 89 | 0.350 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2008 | 380 | 0.330 |
Why?
|
| Biopsy | 1 | 2013 | 1187 | 0.330 |
Why?
|
| Otolaryngology | 2 | 2022 | 55 | 0.330 |
Why?
|
| Neurofibrillary Tangles | 3 | 2008 | 45 | 0.330 |
Why?
|
| Alzheimer Disease | 4 | 2008 | 482 | 0.300 |
Why?
|
| Peptide Fragments | 2 | 2006 | 460 | 0.290 |
Why?
|
| Office Visits | 2 | 2024 | 50 | 0.280 |
Why?
|
| Skull Base | 4 | 2022 | 48 | 0.270 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2276 | 0.260 |
Why?
|
| Humans | 32 | 2024 | 88354 | 0.250 |
Why?
|
| Caspases | 1 | 2004 | 156 | 0.240 |
Why?
|
| Meningioma | 2 | 2016 | 61 | 0.240 |
Why?
|
| Adenoma | 1 | 2024 | 242 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 460 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 111 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 511 | 0.190 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 172 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 577 | 0.190 |
Why?
|
| Brain Injuries | 1 | 2023 | 162 | 0.190 |
Why?
|
| Injury Severity Score | 1 | 2021 | 129 | 0.180 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2023 | 227 | 0.180 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 64 | 0.180 |
Why?
|
| Gene Fusion | 1 | 2019 | 39 | 0.170 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2019 | 25 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 2631 | 0.170 |
Why?
|
| Myosin Heavy Chains | 1 | 2019 | 92 | 0.170 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 65 | 0.170 |
Why?
|
| Drainage | 1 | 2020 | 157 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 124 | 0.160 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2018 | 25 | 0.160 |
Why?
|
| Cranial Fossa, Middle | 1 | 2018 | 11 | 0.160 |
Why?
|
| Telemedicine | 1 | 2021 | 179 | 0.160 |
Why?
|
| Skull | 1 | 2020 | 251 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 339 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1142 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3429 | 0.150 |
Why?
|
| Male | 10 | 2024 | 41885 | 0.150 |
Why?
|
| Seizures | 1 | 2020 | 302 | 0.150 |
Why?
|
| Middle Aged | 6 | 2024 | 25607 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 66 | 0.140 |
Why?
|
| Professional Corporations | 1 | 2016 | 1 | 0.140 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2016 | 3 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 264 | 0.140 |
Why?
|
| Cranial Nerve Diseases | 1 | 2016 | 8 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 661 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 2016 | 63 | 0.130 |
Why?
|
| Nose | 1 | 2016 | 94 | 0.130 |
Why?
|
| Child | 4 | 2022 | 7076 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 131 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 126 | 0.120 |
Why?
|
| Precision Medicine | 2 | 2016 | 407 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 258 | 0.110 |
Why?
|
| Glasgow Coma Scale | 2 | 2023 | 69 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2015 | 183 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2013 | 62 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 126 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 448 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 340 | 0.100 |
Why?
|
| Female | 8 | 2024 | 45612 | 0.100 |
Why?
|
| Adult | 6 | 2024 | 26257 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 773 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2013 | 443 | 0.090 |
Why?
|
| Amino Acid Sequence | 3 | 2009 | 2061 | 0.090 |
Why?
|
| Mutation | 6 | 2016 | 4092 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2021 | 2832 | 0.080 |
Why?
|
| Antibody Specificity | 2 | 2008 | 130 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2024 | 8851 | 0.080 |
Why?
|
| Gliosis | 1 | 2008 | 35 | 0.080 |
Why?
|
| Nitrates | 1 | 2008 | 35 | 0.080 |
Why?
|
| Protein Folding | 1 | 2009 | 282 | 0.080 |
Why?
|
| Astrocytes | 1 | 2008 | 141 | 0.070 |
Why?
|
| Epitopes | 2 | 2004 | 255 | 0.070 |
Why?
|
| Aminopeptidases | 1 | 2006 | 17 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2006 | 63 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1857 | 0.070 |
Why?
|
| Protein Conformation | 2 | 2006 | 884 | 0.070 |
Why?
|
| Disease Progression | 2 | 2015 | 1488 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 1019 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3028 | 0.070 |
Why?
|
| Exome | 2 | 2016 | 127 | 0.060 |
Why?
|
| Caspase 6 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2004 | 24 | 0.060 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2016 | 39 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2004 | 76 | 0.060 |
Why?
|
| Current Procedural Terminology | 1 | 2024 | 12 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2004 | 150 | 0.060 |
Why?
|
| Kinetics | 1 | 2006 | 1528 | 0.060 |
Why?
|
| Binding Sites | 1 | 2006 | 1112 | 0.060 |
Why?
|
| Neurotoxins | 1 | 2003 | 49 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2004 | 174 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 338 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2402 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 427 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6704 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2023 | 80 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 53 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 18875 | 0.050 |
Why?
|
| Death | 1 | 2023 | 84 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2003 | 204 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2006 | 1294 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 477 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 1401 | 0.050 |
Why?
|
| Receptors, Drug | 1 | 2001 | 54 | 0.050 |
Why?
|
| Resuscitation | 1 | 2022 | 105 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2001 | 50 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 266 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 275 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 223 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 226 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2001 | 268 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1253 | 0.050 |
Why?
|
| Young Adult | 2 | 2023 | 6179 | 0.040 |
Why?
|
| Neoplasms | 1 | 2015 | 2995 | 0.040 |
Why?
|
| Length of Stay | 1 | 2023 | 726 | 0.040 |
Why?
|
| Spinal Injuries | 1 | 2020 | 20 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2023 | 389 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 78 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 2020 | 54 | 0.040 |
Why?
|
| Patient Selection | 1 | 2023 | 689 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 77 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 117 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 233 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2020 | 161 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2530 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1713 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 175 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2016 | 30 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 3652 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1565 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 62 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 175 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1588 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 139 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 5301 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 105 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 371 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 104 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1754 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2016 | 206 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 531 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2013 | 97 | 0.030 |
Why?
|
| Smoothened Receptor | 1 | 2013 | 6 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 283 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 698 | 0.030 |
Why?
|
| Neurofibromin 2 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 901 | 0.030 |
Why?
|
| PC12 Cells | 2 | 2003 | 115 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 241 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 202 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 4262 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2285 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 611 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 766 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2004 | 797 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2015 | 546 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 813 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 740 | 0.020 |
Why?
|
| Adolescent | 1 | 2023 | 9131 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1704 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 863 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 1131 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1423 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 272 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2331 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2015 | 1367 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2009 | 208 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 59 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2008 | 56 | 0.020 |
Why?
|
| Tyrosine | 1 | 2008 | 133 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1659 | 0.020 |
Why?
|
| Genomics | 1 | 2013 | 740 | 0.020 |
Why?
|
| Puromycin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 8135 | 0.020 |
Why?
|
| Rats | 2 | 2003 | 4027 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 3667 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2004 | 8 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2004 | 64 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 3360 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 324 | 0.010 |
Why?
|
| Nitroblue Tetrazolium | 1 | 2003 | 2 | 0.010 |
Why?
|
| Ginkgo biloba | 1 | 2003 | 5 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1787 | 0.010 |
Why?
|
| Diffusion | 1 | 2003 | 93 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 228 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 341 | 0.010 |
Why?
|
| Body Temperature | 1 | 2003 | 125 | 0.010 |
Why?
|
| Animals | 3 | 2013 | 27129 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 95 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 438 | 0.010 |
Why?
|
| Imidazoline Receptors | 1 | 2001 | 2 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1128 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 33 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2001 | 111 | 0.010 |
Why?
|
| Clonidine | 1 | 2001 | 33 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 137 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2003 | 244 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 115 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 980 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 151 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 272 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 696 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 11685 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1763 | 0.010 |
Why?
|